Follow Newser on Twitter   Friend Newser on Facebook
Snappy newsletters. Simple Facebook sharing. Spirited comments. Sweet features are waiting… GET THEM NOW!

Many Cancer Trials Go Unpublished: Study

Negative outcomes often shelved because they don't boost careers

By Wesley Oliver,  Newser Staff

Posted Sep 27, 2008 4:45 PM CDT

(Newser) – Fewer than 20% of cancer trial results are published in peer-review journals, a new study says. And industry-sponsored trials only achieve publication one time in 20. The reason? Scientists seeking success and media-hungry journals don't want to publish negative results, analysts say—even if they would aid other cancer studies.

"I knew that there was underpublication," but not at such high rates, study author Dr. Scott Ramsey told BusinessWeek. "We were really shocked by that." Studies that negated a drug's effects may have gone unpublished, he said, while positive ones were. Then "not only are we wasting lots of money, but we'd be giving patients false hopes about the value of the products."

Many science journals refuse to publish negative results. There are some journals which say, 'If you have negative results, we don't want to publish them,' said one researcher. It's dysfunctional.
Many science journals refuse to publish negative results. "There are some journals which say, 'If you have negative results, we don't want to publish them,'" said one researcher. "It's dysfunctional."   (Index Stock)
The findings are particularly worrisome for cancer patients, given that many expensive new drugs have only modest survival benefits, adding at best a few months of life.
The findings are particularly worrisome for cancer patients, given that many expensive new drugs have only modest survival benefits, adding at best a few months of life.   (Shutter Stock)
Experts say there are powerful incentives for researchers not to publish negative results, especially because scientists gain career advancement, money, and fame by making bold advances.
Experts say there are powerful incentives for researchers not to publish negative results, especially because scientists gain career advancement, money, and fame by making bold advances.   (Index Stock)
This clinical trial blackout is a huge problem in cancer research, BusinessWeek reports.
This clinical trial blackout is a huge problem in cancer research, BusinessWeek reports.   (Shutter Stock)
« Prev« Prev | Next »Next » Slideshow
To report an error on this story, notify our editors.
A snapshot of the day's best news stories.
 
COMMENTS
Be the first to comment on this story.

More Newser Stories

US Prescription Drugs Tested on World's Poor

FDA Takes Over 3 Tylenol Plants

When Clinical Trials Kill

Avandia Woes Mount Ahead of FDA Hearing

Anti-Smoking Chantix, Zyban Pose Suicide Risk: FDA


NEWS FROM OUR PARTNERS
Other Sites We Like:   24/7 Wall St.   |   BuzzFeed   |   Cracked   |   Timelines   |   Geek Sugar   |   Business Insider   |   HuffPost Entertainment